Success Metrics

Clinical Success Rate
100.0%

Based on 18 completed trials

Completion Rate
100%(18/18)
Active Trials
0(0%)
Results Posted
67%(12 trials)

Phase Distribution

Ph phase_2
8
44%
Ph phase_1
6
33%
Ph phase_3
4
22%

Phase Distribution

6

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
6(33.3%)
Phase 2Efficacy & side effects
8(44.4%)
Phase 3Large-scale testing
4(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

18 of 18 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(18)

Detailed Status

Completed18

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (33.3%)
Phase 28 (44.4%)
Phase 34 (22.2%)

Trials by Status

completed18100%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT02219490Phase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT02167945Phase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT01939197Phase 2

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Completed
NCT02517528Phase 3

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Completed
NCT00851890Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT01563536Phase 2

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Completed
NCT01911845Phase 2

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Completed
NCT01773070Phase 3

A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

Completed
NCT00696904Phase 1

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

Completed
NCT02534870Phase 1

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Completed
NCT01464827Phase 2

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Completed
NCT01074008Phase 2

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Completed
NCT01306617Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT00726882Phase 2

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

Completed
NCT02052349Phase 1

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Completed
NCT00919490Phase 1

A Study of Single Dose of ABT-333 in Healthy Male Adults

Completed
NCT00909636Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

Completed
NCT00768690Phase 1

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18